Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children

Journal of Chemotherapy

Volumn 10, Issue 2, 1998, Pages 108-113

  Principi, N ^a   Marchisio, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Ceftazidime; Children; Empiric antibiotic treatment; Meropenem; Pediatric infections; Pediatric patients

Indexed keywords

CEFTAZIDIME; MEROPENEM;

ABDOMINAL INFECTION; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA MULTIFORME; FACE EDEMA; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; SEPSIS; SKIN INFECTION; THROMBOCYTOSIS; URINARY TRACT INFECTION;

EID: 0031944025     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.2.108     Document Type: Article

References (15)

1. Adam D. Challenges in the management of serious infections in pediatric patients. Pediatr Infect Dis J 1996; 15: 729-32.
2. Heusser MF, Patterson JE, Kuritza AP, Edberg SC, Baltimore RS. Emergence of resistance to multiple β-lactams in Enterobacter cloacae during treatment for neonatal meningitis with cefotaxime. Pediatr Infect Dis J 1990; 9: 509-12.
3. Sirot DL, Goldstein FW, Soussy CJ, et al. Resistance to cefotaxime and seven other β-lactams in members of the family Enterobacteriaceae: a 3-year survey in France. Antimicrob Agents Chemother 1992; 36: 1677-81.
4. Thomson KS, Sanders CC, Washington JA. High-level resistance to cefotaxime and ceftazidime in Klebsiella pneumonias isolates from Cleveland, Ohio. Antimicrob Agents Chemother 1991; 35: 1001-3.
5. Figueiredo AMS, Connor JD, Severin A, Pato MVV, Tomasz A. A pneumococcal isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob Agents Chemother 1992; 36: 886-9.
6. Frienland IR, Klugman KP. Advance in the management of penicillin-resistant pneumococcal meningitis. South Afr Med J 1992; 81: 341-2.
7. Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49: 577-617.
8. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36 (suppl. A): 1-17.
9. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36 (suppl. A): 207-223.
10. Fujii R, Yoshioka H, Fujiita K, et al. Pharmacokinetic and clinical studies with meropenem in the pediatric field. J Antibiot 1992; 45: 697-717.
11. Bradley JS, Faulkner KL, Klugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996; 15: 749-57.
12. Hoiby N, Johansen H K, Koch C, Jensen T, Pressler T. Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis. Pediatr Infect Dis J 1996; 15: 738-43.
13. Cometta A, Viscoli C, Castagnola E, et al. Empirical treatment of fever in neutropenic children: the role of the carbapenems. Pediatr Infect Dis J 1996; 15: 744-8.
14. Nalin DR, Jacobsen CA. Imipenem/cilastatin therapy for serious infections in neonates and infants. Scand J Infect Dis 1987; (Suppl) 52: 46-55.
15. Wong VK, Wright HT, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10: 122-5.